 SAN DIEGO, CA, Sept. 29, 2021 GLOBE NEWSWIRE -- Skye Bioscience, Inc. OTCQB: SKYE SKYE or the Company, a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today announced the closing of its previously announced registered direct offering for the purchase and sale of 77,777,779 shares of its common stock or common stock equivalents in lieu thereof and warrants to purchase up to an aggregate of 77,777,779 shares of common stock, at an effective purchase price of 0.09 per share or common stock equivalent in lieu thereof and associated warrant. 